Investigation of the efficacy and safety of ipragliflozin combination therapy in case of insufficient glycemic control by DPP-4 inhibitors
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 20 Oct 2016
Price : $35 *
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Oct 2016 Status changed from recruiting to completed.
- 25 Aug 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan.
- 13 Aug 2014 New trial record